57 related articles for article (PubMed ID: 38722288)
1. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development.
Xiang D; He A; Zhou R; Wang Y; Xiao X; Gong T; Kang W; Lin X; Wang X; ; Liu L; Chen YG; Gao S; Liu Y
Theranostics; 2024; 14(8):3300-3316. PubMed ID: 38855182
[TBL] [Abstract][Full Text] [Related]
2. Tumor Organoid as a Drug Screening Platform for Cancer Research.
Mahbubi R; Yousefi N; Hamidieh AA; Gholizadeh F; Sisakht MM
Curr Stem Cell Res Ther; 2023 Oct; ():. PubMed ID: 37855289
[TBL] [Abstract][Full Text] [Related]
3. [Application and Research Progress of Lung Cancer Organoid in Precision Medicine
for Lung Cancer].
Huang Z; Li B; Wang Y; Xue J; Wei Z; Liang N; Li S
Zhongguo Fei Ai Za Zhi; 2024 Apr; 27(4):276-282. PubMed ID: 38769830
[TBL] [Abstract][Full Text] [Related]
4. Preclinical models for bladder cancer therapy research.
Ertl I; Shariat SF; Berger W; Englinger B
Curr Opin Urol; 2024 Jul; 34(4):244-250. PubMed ID: 38630912
[TBL] [Abstract][Full Text] [Related]
5. Drug screening on digital microfluidics for cancer precision medicine.
Zhai J; Liu Y; Ji W; Huang X; Wang P; Li Y; Li H; Wong AH; Zhou X; Chen P; Wang L; Yang N; Chen C; Chen H; Mak PI; Deng CX; Martins R; Yang M; Ho TY; Yi S; Yao H; Jia Y
Nat Commun; 2024 May; 15(1):4363. PubMed ID: 38778087
[TBL] [Abstract][Full Text] [Related]
6. The future of cancer therapy: exploring the potential of patient-derived organoids in drug development.
Avci CB; Bagca BG; Shademan B; Takanlou LS; Takanlou MS; Nourazarian A
Front Cell Dev Biol; 2024; 12():1401504. PubMed ID: 38835507
[TBL] [Abstract][Full Text] [Related]
7. Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of Cancer.
Colling KE; Symons EL; Buroni L; Sumanasiri HK; Andrew-Udoh J; Witt E; Losh HA; Morrison AM; Leslie KK; Dunnill CJ; de Bono JS; Thiel KW
J Vis Exp; 2024 Jan; (203):. PubMed ID: 38251777
[TBL] [Abstract][Full Text] [Related]
8. Multiplexed live-cell imaging for drug responses in patient-derived organoid models of cancer.
Colling KE; Symons EL; Buroni L; Sumanisiri HK; Andrew-Udoh J; Witt E; Losh HA; Morrison AM; Leslie KK; Dunnill CJ; De Bono JS; Thiel KW
bioRxiv; 2023 Nov; ():. PubMed ID: 38014133
[TBL] [Abstract][Full Text] [Related]
9. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment.
Cui Y; Ran R; Da Y; Zhang H; Jiang M; Qi X; Zhang W; Niu L; Zhou Y; Zhou C; Tang X; Wang K; Yan Y; Ren Y; Dong D; Zhou Y; Wang H; Gong J; Hu F; Zhao S; Zhang H; Zhang C; Yang J
J Cell Mol Med; 2024 May; 28(9):e18374. PubMed ID: 38722288
[TBL] [Abstract][Full Text] [Related]
10. Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
Novoplansky O; Shnerb AB; Marripati D; Jagadeeshan S; Abu Shareb R; Conde-López C; Zorea J; Prasad M; Ben Lulu T; Yegodayev KM; Benafsha C; Li Y; Kong D; Kuo F; Morris LGT; Kurth I; Hess J; Elkabets M
Mol Oncol; 2023 Dec; 17(12):2618-2636. PubMed ID: 37501404
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA-mutations in breast cancer.
Reinhardt K; Stückrath K; Hartung C; Kaufhold S; Uleer C; Hanf V; Lantzsch T; Peschel S; John J; Pöhler M; Bauer M; Bürrig FK; Weigert E; Buchmann J; Kantelhardt EJ; Thomssen C; Vetter M
Breast Cancer Res Treat; 2022 Dec; 196(3):483-493. PubMed ID: 36279023
[TBL] [Abstract][Full Text] [Related]
12. Individualized therapy based on the combination of mini-PDX and NGS for a patient with metastatic AFP-producing and HER-2 amplified gastric cancer.
Zhu X; Xu X; Zhang B; Dong Y; Gong S; Gong T; Zhang F; Jin C
Oncol Lett; 2022 Nov; 24(5):411. PubMed ID: 36245818
[TBL] [Abstract][Full Text] [Related]
13. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer.
Liu SL; Liang HB; Yang ZY; Cai C; Wu ZY; Wu XS; Dong P; Li ML; Zheng L; Gong W
Int J Med Sci; 2022; 19(2):286-298. PubMed ID: 35165514
[TBL] [Abstract][Full Text] [Related]
15. OncoVee™-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients With Synchronous Liver Metastases: A Retrospective Cohort Analysis.
Ge Y; Zhang X; Liang W; Tang C; Gu D; Shi J; Wei X
Front Oncol; 2021; 11():757383. PubMed ID: 35047388
[TBL] [Abstract][Full Text] [Related]
16. Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer.
Chen P; Zhang X; Ding R; Yang L; Lyu X; Zeng J; Lei JH; Wang L; Bi J; Shao N; Shu D; Wu B; Wu J; Yang Z; Wang H; Wang B; Xiong K; Lu Y; Fu S; Choi TK; Lon NW; Zhang A; Tang D; Quan Y; Meng Y; Miao K; Sun H; Zhao M; Bao J; Zhang L; Xu X; Shi Y; Lin Y; Deng C
Adv Sci (Weinh); 2021 Nov; 8(22):e2101176. PubMed ID: 34605222
[TBL] [Abstract][Full Text] [Related]
17. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
Jacquemetton J; Kassem L; Poulard C; Dahmani A; De Plater L; Montaudon E; Sourd L; Morisset L; El Botty R; Chateau-Joubert S; Vacher S; Bièche I; Treilleux I; Trédan O; Marangoni E; Le Romancer M
Breast Cancer Res; 2021 May; 23(1):57. PubMed ID: 34020697
[TBL] [Abstract][Full Text] [Related]
18. Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER
Servetto A; Kollipara R; Formisano L; Lin CC; Lee KM; Sudhan DR; Gonzalez-Ericsson PI; Chatterjee S; Guerrero-Zotano A; Mendiratta S; Akamatsu H; James N; Bianco R; Hanker AB; Kittler R; Arteaga CL
Clin Cancer Res; 2021 Aug; 27(15):4379-4396. PubMed ID: 34011560
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
